# HDR Brachytherapy, EBRT and STAD for the Treatment of Prostate Cancer

> **NCT03553602** · PHASE1,PHASE2 · TERMINATED · sponsor: **Loyola University** · enrollment: 3 (actual)

## Conditions studied

- Prostate Cancer - Recurrent

## Interventions

- **DRUG:** HDR Brachytherapy + EBRT + STAD

## Key facts

- **NCT ID:** NCT03553602
- **Lead sponsor:** Loyola University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-12-20
- **Primary completion:** 2024-07-26
- **Final completion:** 2024-07-26
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** The study was stopped for feasibility
- **Last updated:** 2026-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03553602

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03553602, "HDR Brachytherapy, EBRT and STAD for the Treatment of Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03553602. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*